BioMarin Pharmaceutical Inc. (BMRN) Stock AnalysisBMRNBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its Galafold (migalastat) is the first oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

BioMarin Pharmaceutical Inc appears to be a good buy at the current price of $64.665, especially considering its strong revenue growth, with Q2 2026 revenue reported at $989.7 million, a 20% increase year-over-year. Additionally, the forward P/E ratio of 13.23 suggests the stock is undervalued compared to its earnings potential. The main risk is the recent increase in debt to equity, which rose to 66.22% in Q2 2026, indicating potential financial strain.

24 analysts cover BMRN: 19 rate it Buy, 5 Hold and 0 Sell. The average price target is 87.35.